Patterns of failure after stereotactic body radiotherapy to non-spine bone metastases

被引:0
|
作者
Perez-Montero, Hector [1 ]
Lozano, Alicia [1 ]
de Blas, Rodolfo [2 ]
Hernandez, Javier [3 ]
Mera, Arantxa [4 ]
Guedea, Ferran [1 ]
Navarro-Martin, Arturo [1 ]
机构
[1] Catalan Inst Oncol, Radiat Oncol Dept, Avinguda Gran Via LHospitalet 199-203, Barcelona 08908, Spain
[2] Catalan Inst Oncol, Med Phys & Radiat Protect Dept, Avinguda Gran Via LHospitalet 199-203, Barcelona 08908, Spain
[3] Bellvitge Univ Hosp, Radiodiagnost Dept, Carrer Feixa Llarga W-N, Barcelona 08907, Spain
[4] Hosp Santa Creu & Sant Pau, Radiat Oncol Dept, St Quinti 89, Barcelona 08025, Spain
关键词
Stereotactic body radiotherapy; Bone metastases; Recurrence patterns; Contouring guidelines; Local control; RADIATION-THERAPY; BREAST-CANCER; DELINEATION; VOLUME; MICROMETASTASES; RECOMMENDATIONS; MULTICENTER; RECURRENCE; DISEASE; IMPACT;
D O I
10.1007/s12094-025-03878-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purposeStereotactic body radiotherapy (SBRT) has proven useful for non-spine bone metastases (NSBM). We analyzed local relapse rates and patterns of failure after NSBM-SBRT, contrasting our results with existing contouring guidelines.Materials and methodsWe conducted a retrospective analysis of NSBM-SBRT treatments performed between 2013 and 2024 in a single institution. Clinical, pathologic, and treatment-related data were collected. Failure patterns were assessed based on imaging tests and categorized as in-field, marginal/out-of-field.ResultsAmong 119 NSBM-SBRT treatments in 85 patients, the most common primary tumors were prostate (36.1%) and breast cancer (24.4%). The coxal bone was the predominant metastatic site (52.9%). The median follow-up was 32.8 months. OS rates at 1, 2, and 3 years were 90.1%, 83.5%, and 75.8%, respectively. Twenty seven relapses were observed in the treated bone with a median recurrent tumor volume of 9.9 cm3 and a median time to recurrence of 15.1 months. Relapse-free survival in the treated bone was 89.4%, 78.5%, and 74.2% at 1, 2, and 3 years, respectively. Median recurrent tumor volume within the CTV was 50.6% and the median distance from the relapse center to the initial tumor was 11.4 mm.ConclusionNSBM-SBRT provides effective local control with relapses often occurring near the initial tumor lesion. While adherence to existing contouring guidelines captures most scenarios, consideration of larger CTV expansions may be warranted in cases with poorer prognosis. Further studies are needed to identify risk factors for relapses outside the margins and optimize volume delineation in these scenarios.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Stereotactic body radiation therapy for non-spine bone oligometastatic disease
    Faivre, J-C
    Marchesi, V
    Thureau, S.
    CANCER RADIOTHERAPIE, 2021, 25 (08): : 837 - 842
  • [22] Radiographic Response Assessment after Stereotactic Body Radiation Therapy for Spine and Non-Spine Bone Metastases: Results from a Single Institutional Study
    Correia, D.
    Moullet, B.
    Jennifer, C.
    Heiss, R.
    Aebersold, D. M.
    Hemmatazad, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E190 - E190
  • [23] Clinical Outcomes of Stereotactic Body Radiation Therapy for Bone and Non-Spine Bone Metastases: A Large Single Institution Experience
    Thomas, M. C.
    Chen, Y. H.
    Fite, E.
    Pangilinan, A. J.
    Bubelo, K.
    Spektor, A.
    Balboni, T. A.
    Huynh, M. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E481 - E481
  • [24] Shifting the Landscape of Spine and Non-Spine Bone Metastases
    Udovicich, Cristian
    Lo, Simon S.
    Guckenberger, Matthias
    Sahgal, Arjun
    CANCER JOURNAL, 2024, 30 (06): : 385 - 392
  • [25] Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases
    Owen, Dawn
    Laack, Nadia N.
    Mayo, Charles S.
    Garces, Yolanda I.
    Park, Sean S.
    Bauer, Heather J.
    Nelson, Kathryn
    Miller, Robert W.
    Brown, Paul D.
    Olivier, Kenneth R.
    PRACTICAL RADIATION ONCOLOGY, 2014, 4 (02) : E143 - E149
  • [26] Palliative Efficacy of High-Dose Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Painful Non-Spine Bone Metastases: A Propensity Score-Matched Analysis
    Ito, Kei
    Taguchi, Kentaro
    Nakajima, Yujiro
    Ogawa, Hiroaki
    Murofushi, Keiko Nemoto
    CANCERS, 2022, 14 (16)
  • [27] The Role of Post-Operative Radiotherapy for Non-Spine Bone Metastases (NSBMs)
    Ramadan, Sherif
    Arifin, Andrew J.
    Nguyen, Timothy K.
    CANCERS, 2023, 15 (13)
  • [28] Computed Tomography Evaluation of Mean Bone Density and Volume on Non-Spine Bone Metastases Following Stereotactic Body Radiation Therapy
    Finkelstein, S.
    Raman, S.
    van der Velden, J. M.
    Zhang, L.
    Tan, C.
    Dhillon, A.
    Tonolete, F.
    Chiu, N.
    Probyn, L.
    McDonald, R.
    Sahgal, A.
    Chow, E.
    Chin, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E566 - E566
  • [29] ACR Appropriateness Criteria® Non-Spine Bone Metastases
    Lutz, Stephen T.
    Lo, Simon Shek-Man
    Chang, Eric L.
    Galanopoulos, Nicholas
    Howell, David D.
    Kim, Edward Y.
    Konski, Andre A.
    Pandit-Taskar, Neeta D.
    Ryu, Samuel
    Silverman, Larry N.
    Van Poznak, Catherine
    Weber, Kristy L.
    JOURNAL OF PALLIATIVE MEDICINE, 2012, 15 (05) : 521 - 526
  • [30] A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial)
    Carole Mercier
    Piet Dirix
    Paul Meijnders
    Peter Vermeulen
    Steven Van Laere
    Hilde Debois
    Philippe Huget
    Dirk Verellen
    Radiation Oncology, 13